Managing ADC Dose Adjustments to Improve Ocular Toxicities

In this segment, the expert faculty reflects on real-world management of ocular toxicities associated with antibody-drug conjugates (ADCs) and the evolving collaboration between oncology and ophthalmology. The ophthalmologist emphasizes the foundational role of preservative-free artificial tears and highlights how ophthalmologists are adapting to a new clinical dynamic—one in which ocular findings may influence continuation or dose modification of life-prolonging cancer therapies. The panel discusses the emotional and clinical complexity of advising patients who fear losing access to an effective ADC despite eye symptoms.

They underscore that dose reductions and short treatment holds rarely compromise efficacy, and ocular abnormalities typically reverse once dosing is adjusted—an encouraging message for both clinicians and patients. The faculty reiterates the importance of shared assessment tools, structured communication forms, and early ophthalmology involvement to contextualize ocular findings against baseline comorbidities. They conclude that proactive, multidisciplinary coordination is essential to safely maintain patients on transformative ADC therapies.